Original Article

Serum C1q and tumor necrosis factor (TNF)-related protein 9 in women with Polycystic Ovary Syndrome

Neda Forouhi a, Ahmad Saedisomeolia a,b, Mahmoud Djalali a, Mohammad Reza Eshraghian c, Nava Morshedzadeh d, Fateme Zabetian-Targhi a, Maryam Mahmoudi a,*

Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
bDepartment of Pharmacy, School of Medicine, Western Sydney University, NWS, Australia
Department of Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

A R T I C L E I N F O

Keywords:
C1q/TNF-related protein 9
Polycystic Ovary Syndrome
Adipokine

A B S T R A C T

Aims: To compare CTRP9 levels in women with Polycystic Ovary Syndrome (PCOS) and without PCOS.
Furthermore, to determine the correlation between serum CTRP9 levels and some variety of anthropometric and biochemical parameters.

Methods: The study included 29 PCOS patients and 27 healthy volunteers of the same age and BMI. Body weight, height and waist circumference were assessed. Blood samples were taken for assessment of serum CTRP9 by enzyme-linked immunosorbent assay (ELISA) technique. In addition, blood samples were collected for fasting insulin, glucose, and lipid profiles, and homeostasis model of assessment-insulin resistance (HOMA-IR) values were calculated.

Results: Similar serum CTRP9 were found in PCOS subjects and controls (8.8 ± 19.9 vs 5.0 ± 7.6 ng/mL). Serum CTRP9 concentration positively correlated with serum LDL-C and total cholesterol in patient group. However, no correlation between CTRP9 and other biochemical and anthropometric variables was found.

Conclusion: Serum CTRP9 logs of PCOS participants exhibit a positive association with unfavorable lipid profile in this report.

© 2016 Diabetes India. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Polycystic ovary syndrome (PCOS), a common endocrine disorder, negatively impact women in reproductive age [1]. According to the European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) criteria, the prevalence of PCOS is estimated 15–20%. The manifestations of the disease include irregular menstrual cycles, anovulatory infertility, polycystic ovaries, biochemical and clinical hyperandrogenism such as hirsutism, to name but a few [2]. PCOS contributes to insulin resistance, resulting in impaired glucose intolerance (IGT), type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome [2,3].

PCOS and metabolic syndrome are similar in creating the conditions for abdominal obesity and dysregulation of adipose tissue function; the latter can induce an alternation in expression and secretion of adipose tissue products termed adipokines or adipokines. With regard to significant effects of altered adipokines on insulin sensitivity, these changes may contribute to metabolic disturbances in PCOS [4,5].

A recent family of adipokines named C1q and tumor necrosis factor (TNF)-related proteins (CTRPs) have been proposed to play a role in energy regulation and particularly glucose metabolism. In addition, CTRPs have displayed anti-inflammatory and insulin sensitivity promoting effects [6,7]. CTRP9, the closest paralog of adiponectin, is suggested to have a correlation with body weight by animal research [8,9]. Moreover, an increase in CTRP9 expression in mice caused a significant reduction in plasma glucose and insulin levels [8,10], through activating AMPK, Akt, and p44/42 MAPK signaling pathways [10].

Studies revealed that there are significant differences in serum CTRP9 concentrations in diabetic patients in comparison with...
healthy controls. The association between serum CTRP9 with metabolic syndrome, homeostasis model assessment for insulin resistance (HOMA-IR), Body Mass Index (BMI), visceral fat amount, fasting serum glucose and some markers of lipid profile had been demonstrated in literature [11,12]. Due to a high prevalence of metabolic syndrome and diabetes in PCOS women [2], it is hypothesized that there would be a difference in serum CTRP9 of subjects with PCOS versus healthy controls. Therefore, we aimed to determine the difference between serum CTRP9 concentrations in PCOS patients and healthy controls. We also aimed to examine the probable relationship between serum CTRP9 levels and some metabolic and anthropometric parameters.

2. Materials and methods

2.1. Subjects

Twenty nine recently diagnosed PCOS women were recruited (age: 18–38 y) from a public clinic of Tehran University of Medical Sciences. These patients have not been under any pharmacological treatment for the disease. The PCOS patients were single out by a gynecologist based on ESHRE/ASRM criteria [13]. The subjects were failed to participate, unless they would satisfied two of the three following criteria: Clinical and/or biochemical hyperandrogenism, Oligo-ovulation or anovulation, ultrasonographic polycystic ovaries. Patients with other androgen excess or related disorders (e.g., congenital adrenal hyperplasia, cushing syndrome) were also excluded.

Twenty seven age- and body mass index (BMI)-matched healthy control women with regular menstrual cycles were enrolled into the study through a public advertisement in the same clinic.

Women with autoimmune, systematic infectious, social and psychological, and endocrine disorders other than PCOS were excluded from both cases and controls. None of the participants were on medications for at least 3 months prior to the study, including oral hypoglycemic agents, reducing fat absorption drugs, anti-inflammatory medications, antioxidant supplements, and oral contraceptives. Other exclusion criteria for two groups were pregnancy and lactation, smoking and alcohol history for at least 6 months prior to the sample collection. The written informed consent forms were signed by all participants at the time of enrollment. Our study was approved by the Ethics Committee of Tehran University of Medical Sciences Vice Chancellor for Research (ID: 9211468014).

2.2. Anthropometric measurements

Anthropometric measurements including body weight, height, and waist circumference were performed. Body weight and height were measured to the accuracies of 0.1 kg and 0.1 cm respectively. Body mass index was computed as weight divided by height squared (kg/m²). Waist circumference was measured to an accuracy of 0.1 cm midpoint between the lowest rib and the iliac crest.

2.3. Clinical and biochemical analysis

After a 10 h overnight fast, blood samples which drawn from the veins of adult female subjects were immediately centrifuged. Aliquots of plasma and serum samples were stored at −80 °C until biochemical analysis.

Serum CTRP9 concentrations were measured using commercial ELISA kit manufactured by Biovendor (Bio Vendor LM, Brno, Czech Republic) according to the instruction of manufacturer. The kit had intra- and inter-assay coefficients of variations of 5.5% and 7.9% respectively. Limitation of detection for the assay was 9 pg/mL. We measured fasting serum glucose concentrations by the glucose oxidase method (Pars Azmoon Inc.; Tehran, Iran) and serum insulin by ELISA kit (Insulin ELISA kit; DiaMetrà, Milan, Italy). The HOMA-IR indexes were calculated by the following formula: HOMA-IR = fasting glucose (mg/dL) × fasting insulin (μU/mL)/405 [14]. Total cholesterol, triglyceride (TG), high-density lipoprotein (HDL)-cholesterol, and low-density lipoprotein (LDL)-cholesterol levels were analyzed respectively using the cholesterol oxidase-phenol + aminophenazone (CHOD PAP), the glyceral-3-phosphate oxidase-phenol + aminophenazone (GPO PAP), immuno, and enzymatic kits on a BIOLIS 24i premium auto-analyzer (Tokyo, Japan).

2.4. Statistical analysis

All statistical analyses were performed using the SPSS statistical package compatible with Windows, version 18 (SPSS Inc. IBM CO). We used Kolmogrov–Smirnov test in order to explore the normality distribution of variables. Log transformation was conducted for skewed distributed variables. The differences in the mean of the variables were compared using a parametric and non-parametric tests; independent student t-test and Mann–Whitney U-test, respectively, according to their distribution. To find the relationships between log transformation of CTRP9 levels and other parameters, Simple Linear Regression model was used. P < 0.05 was regarded as statistically significant. All data are presented as mean ± standard deviation.

3. Results

The demographic, clinical, and anthropometric characteristics of participants are provided in Table 1. The means of CTRP9 levels were 8.8 ± 19.9 ng/mL in PCOS and 5.0 ± 7.6 ng/mL in control groups, respectively. These levels ranged from 0.025 to 82.3 ng/mL in patients and 0.025 to 31.1 ng/mL in control subjects.

Fasting serum CTRP9 concentration differences were not significant in two groups (P > 0.05). Among other biochemical parameters, serum levels of triglycerides were significantly higher (P = 0.01) and HDL-C levels were significantly lower (P = 0.01) in PCOS subjects than controls.

Age and BMI did not statistically differ between PCOS and control groups. However, PCOS women had significantly higher waist circumferences than healthy controls (P < 0.001).

Using linear regression, serum CTRP9 levels showed no significant correlation with age and anthropometric variables. Serum concentrations of CTRP9 positively correlated with serum LDL-C (B = 0.019; P = 0.03) and total cholesterol in PCOS group.

Table 1

Basic, anthropometric and biochemical characteristics of patients and controls.

<table>
<thead>
<tr>
<th></th>
<th>PCOS</th>
<th>Control</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>29</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Age (year)</td>
<td>26.2±4.1</td>
<td>27.1±5.0</td>
<td>0.46</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162.5±6.2</td>
<td>161.9±5.9</td>
<td>0.83</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>71.4±13.5</td>
<td>67.3±10.4</td>
<td>0.21</td>
</tr>
<tr>
<td>Waist Circumstance (cm)</td>
<td>93.5±8.2</td>
<td>80.6±9.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI</td>
<td>26.9±4.2</td>
<td>25.6±3.8</td>
<td>0.23</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>133.4±8.0</td>
<td>91.5±43.9</td>
<td>0.01</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>184.2±35.2</td>
<td>179.7±35.0</td>
<td>0.63</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>100.7±23.7</td>
<td>96.4±22.6</td>
<td>0.49</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>41.7±7.0</td>
<td>48.7±12.4</td>
<td>0.01</td>
</tr>
<tr>
<td>Fasting blood sugar (mg/dL)</td>
<td>87.7±11.1</td>
<td>73.5±27.1</td>
<td>0.10</td>
</tr>
<tr>
<td>Fasting insulin (μU/mL)</td>
<td>8.6±1.6</td>
<td>18.4±26.2</td>
<td>0.43</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.1±0.18</td>
<td>1.4±1.1</td>
<td>0.61</td>
</tr>
<tr>
<td>CTRP9 (ng/mL)</td>
<td>8.8±19.9</td>
<td>5.0±7.6</td>
<td>0.74</td>
</tr>
</tbody>
</table>

PCOS: Polycystic Ovary Syndrome; BMI: body mass index; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; CTRP9: C1q and tumor necrosis factor (TNF)-related protein 9.

Please cite this article in press as: Forouhi N, et al. Serum C1q and tumor necrosis factor (TNF)-related protein 9 in women with Polycystic Ovary Syndrome. Diab Met Syndr: Clin Res Rev (2016), http://dx.doi.org/10.1016/j.dsx.2016.03.012
Table 2
Correlation between serum CTRP9 and basic, anthropometric and biochemical variables in women with PCOS and healthy controls.

<table>
<thead>
<tr>
<th></th>
<th>PCOS n=29</th>
<th>Control n=27</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B coefficient</td>
<td>P-value</td>
</tr>
<tr>
<td>Age (year)</td>
<td>-0.096</td>
<td>NS</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>-7.62</td>
<td>3.2</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>0.001</td>
<td>NS</td>
</tr>
<tr>
<td>Waist circumstance (cm)</td>
<td>2.3</td>
<td>NS</td>
</tr>
<tr>
<td>Body mass index</td>
<td>0.019</td>
<td>NS</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>1.87</td>
<td>0.05</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>0.015</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>0.019</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>-0.064</td>
<td>NS</td>
</tr>
<tr>
<td>Fasting blood sugar (mg/dL)</td>
<td>-4.3</td>
<td>NS</td>
</tr>
<tr>
<td>Fasting insulin (μU/mL)</td>
<td>-0.038</td>
<td>NS</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>-1.2</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS: not significant.

(B = 0.015; P = 0.009). Although, P-values for Triglycerides in both groups and those of total cholesterol in controls were 0.05, these correlations were statistically insignificant. There were no correlations between CTRP9 and other biochemical values (Table 2).

4. Discussion

Our study provides evidence that CTRP9 (C1q and tumor necrosis factor (TNF)-related protein 9) levels were higher in PCOS patients as compared to their age and BMI-matched controls. However, this finding failed to be statistically significant. An increase in CTRP9 may be a compensatory response to overcome atherogenic condition of the disease. Nonetheless, Hwang et al. revealed that normal glucose tolerance group had significantly higher CTRP9 concentrations when compared to prediabetes and type 2 diabetes population. Additionally, there were no differences in CTRP9 mean values between prediabetes subjects and diabetic patients in their study [11]. With respect to high prevalence of dysglycemia and type 2 diabetes in PCOS patients [2], further research is needed to indicate the role of CTRP9 in glucose metabolism.

We did not indicate any association between CTRP9 and fasting insulin, plasma glucose and HOMA-IR. These results may be influenced by favorable glucose phenotype in our PCOS participants. However, in the studies of Peterson et al. and Wong et al., mice with overexpression of CTRP9 had markedly reduced fasting insulin and glucose values [8,10] and increased systemic insulin sensitivity [8]. The association of CTRP9 with HOMA-IR in human was explored in two different cross-sectional studies. One of which demonstrated an inverse correlation [11]. On the other hand, another one showed that serum CTRP9 positively correlated with HOMA-IR [12]. Therefore, the relationship between CTRP9 and these parameters remains a divisive issue and warrants more research.

Our findings showed that CTRP9 positively correlated with total cholesterol (TC) and LDL-C in PCOS group. Moreover, the results indicated a weak association of CTRP9 and TG. Future studies are needed to demonstrate the exact relation. In transgenic mice model, an increase in expression of CTRP9 resulted in a reduction in liver and muscle triglycerides (TGs) and a rise in fat oxidation [8]. Contrary to our findings, the results of Hwang’s study suggested an inverse correlation between serum CTRP9 and TC, LDL-C and TG. As to positive association of CTRP9 with TC and LDL-C, our findings appear to confirm the evidence of CTRP9 resistance suggested in a previous study [12].

Present study revealed no relationship between serum CTRP9 concentrations and anthropometric variables. By contrast, diet-induced obese mice model had significantly reduced circulatory CTRP9 levels [8]. Unlike our results, levels of CTRP9 were positively correlated with BMI [11] and negatively correlated with visceral fat amount [12] in previous studies. With regard to the findings of other studies, serum CTRP9 levels are likely to be associated with body size in human. The mechanisms involved in this issue have to be investigated further.

It has been suggested that adipose tissue dysfunction and consequent alternations in expression and secretion of adipocytokines contributes to metabolic disturbances observed in PCOS [15]. Accordingly, several studies have been conducted to examine new adipokines in this syndrome [16–20]. The present study is the first to measure serum concentrations of a novel adipokine, CTRP9 derived from adipose tissue in PCOS subjects.

The limitations of our report can be summarized as follows: The first limitation of this study is its small sample size of study due to our inclusion and exclusion criteria. In addition, two PCOS and control subgroups included obese and non-obese seem to be helpful for better comparison. The second limitation of this study is derived from the fact that metabolic profiles of PCOS group were relatively optimal. The third limitation of this study is the lack of causal effect detection in this study due to the design of study which is an observational study. Finally, we regret that we were unable to measure hormonal status of participants due to the limitation of resources.

In conclusion, the present study revealed that there were no difference in serum levels of CTRP9 in PCOS women compared to those of healthy controls. The positive associations between this adipokine and some components of serum lipid profiles, LDL-C and TC, are observed in present case-control study for the first time. Further studies are required to investigate the mechanistic action of CTRP9 in PCOS.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgment

This research has been supported by Tehran University of Medical Sciences & Health Services (grant no: 93-04-161-27773).

References


